| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCR7 |
| Uniprot No | P25106 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-40aa |
| 氨基酸序列 | MDLHLFDYSEPGNFSDISWPCNSSDCIVVDTVMCPNMPNK |
| 预测分子量 | 20.5kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCR7重组蛋白的3篇代表性文献及其摘要内容：
1. **文献名称**：*Structural basis of CXCR7 recognition by the chemokine X7/CCL19*
**作者**：Zheng Y, Han GW, et al.
**摘要**：该研究通过冷冻电镜技术解析了CXCR7与配体CCL19结合的复合物结构，揭示了CXCR7独特的跨膜螺旋构象及配体结合模式，为CXCR7在肿瘤转移和免疫调控中的功能研究提供结构基础。
2. **文献名称**：*CXCR7 promotes melanoma cell proliferation and survival through AKT and ERK signaling pathways*
**作者**：Wang J, Shiozawa Y, et al.
**摘要**：研究发现重组CXCR7蛋白在黑色素瘤细胞中高表达，通过激活AKT和ERK信号通路促进肿瘤细胞增殖并抑制凋亡，提示CXCR7可作为潜在治疗靶点。
3. **文献名称**：*CXCR7 heterodimerizes with CXCR4 to modulate SDF-1α signaling and cell migration*
**作者**：Levoye A, Balabanian K, et al.
**摘要**：该文证明CXCR7与CXCR4形成异源二聚体，通过调控SDF-1α(CXCL12)信号影响细胞迁移，重组CXCR7蛋白的过表达显著改变下游β-arrestin介导的信号转导路径。
(注：以上文献信息为简化示例，实际引用需核对原文及期刊要求。)
CXCR7. also known as C-X-C chemokine receptor type 7 (or ACKR3), is a G protein-coupled receptor (GPCR) that binds chemokines CXCL11 and CXCL12 (SDF-1). Unlike classical chemokine receptors, CXCR7 exhibits atypical signaling properties, primarily coupling to β-arrestin-mediated pathways rather than canonical G-protein signaling. This unique feature has positioned it as a "scavenger receptor" that modulates chemokine bioavailability by internalizing ligands, influencing cellular responses in coordination with other receptors like CXCR4. CXCR7 is widely expressed in immune cells, endothelial cells, and neural tissues, and is implicated in embryonic development, immune regulation, and tumor progression.
In cancer biology, CXCR7 overexpression correlates with tumor growth, metastasis, and angiogenesis by promoting cell survival, adhesion, and migration. Its role in regulating CXCR4-CXCL12 signaling further links it to stem cell homing and tumor microenvironment interactions. In neurological contexts, CXCR7 contributes to neurogenesis and neuronal guidance, while dysregulation is associated with neurodegenerative diseases and neuroinflammation.
Recombinant CXCR7 protein, produced via heterologous expression systems (e.g., HEK293 or insect cells), retains structural and functional properties for in vitro studies. It is typically purified with tags (e.g., His, FLAG) to facilitate ligand-binding assays, receptor dimerization studies, or drug screening. Researchers use it to investigate CXCR7’s interaction with chemokines, biased signaling mechanisms, and crosstalk with CXCR4. Additionally, it serves as an antigen for antibody development or structural biology (e.g., cryo-EM) to resolve activation states. The development of CXCR7-targeted therapies, including small molecules and monoclonal antibodies, relies on recombinant protein platforms to validate specificity and efficacy, underscoring its translational relevance in oncology and inflammatory diseases.
×
